Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort

BACKGROUND: Benefit of carboplatin and dose-dense weekly paclitaxel (ddCT) in first line treatment of ovarian cancer patients has been different in Western and Asian studies. In the present study we compare progression-free survival (PFS) of ddCT to three-weekly carboplatin and paclitaxel (CT) in fi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Pirolli, Rafaela, de Alencar, Viviane Teixeira Loiola, Estati, Felipe Leonardo, Ribeiro, Adriana Regina Gonçalves, Honda, Daniella Yumi Tsuji, de Oliveira, Mariana, da Silveira Nogueira Lima, Joao Paulo, dos Santos, Elizabeth Santana, Guimarães, Andrea Paiva Gadelha, Baiocchi, Glauco, da Costa, Alexandre André Balieiro Anastácio
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106841/
https://ncbi.nlm.nih.gov/pubmed/33964923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08270-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados